If not, please take a few moments to fill out the form below. It’s free, and ensures that you receive regular alerts to the latest clinical news and other content.

Keep me logged in Forgot your password?

Please wait...

Please wait...

Fesoterodine Relieves Nocturnal Urgency in OAB Patients

May 23, 2012

Flexible-dose fesoterodine is superior to placebo in decreasing the number of nocturnal urgency episodes and nocturnal micturitions in patients with overactive bladder (OAB), researchers reported at the American Urological Association 2012 annual meeting.
 

OAB Patients Most Bothered by Urgency

May 23, 2012

Patients with overactive bladder (OAB) say they are most bothered by symptoms of urinary urgency either as a primary complaint or as a driving symptom for frequency, according to a pilot study presented at the American Urological Association 2012 annual meeting.
 

BoNTA Safe, Effective for Diabetic OAB Patients

May 23, 2012

Diabetes has no influence on intravesical botulinum toxin type A (BoNTA) injection in overactive bladder (OAB) patients, researchers reported at the American Urological Association 2012 annual meeting.
 

Oxybutynin Gel Eases Urinary Incontinence

May 21, 2012

A new oxybutynin gel (OTG) with propylene glycol to aid transdermal delivery, which dispensed via a pump, is effective for treating urgency and mixed urinary incontinence (UI), according to the findings of a phase 3 study presented at the American Urological Association 2012 annual meeting.
 

OAB Sufferers Less Physically Active

May 19, 2012

Men and women with overactive bladder (OAB) are significantly less likely to achieve recommended physical activity levels than those with no or minimal symptoms (NMS) of OAB, according to a poster presentation at the American Urological Association 2012 annual meeting.
 

Transdermal Gel for Overactive Bladder Launched

April 27, 2012

Watson Pharmaceuticals of Parsippany, N.J., and Antares Pharma. Inc. of Ewing, NJ, have announced the launch of Gelnique (oxybutynin), a transdermal gel for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency.
 

Novel Drug for Overactive Bladder Works Even If Antimuscarinics Do Not

February 29, 2012

PARIS—Mirabegron, an experimental drug for overactive bladder (OAB), can effectively treat the condition in patients whether or not they failed previous antimuscarinic therapy, according to findings presented at the 27th Annual Congress of the European Association of Urology.
 

Repeated Toxin Injections Safe and Effective for Refractory Overactive Bladder

December 26, 2011

Repeated injections of botulinum toxin type A (BoNTA) are safe and effective for the medium-term management of refractory overactive bladder (OAB) and idiopathic detrusor overactivity (IDO), according to British investigators.
 

Overactive Bladder Linked to Metabolic Syndrome in Women

November 01, 2011

Metabolic syndrome is associated with overactive bladder (OAB) in women, according to researchers.
 

Botulinum Toxin Effective in OAB Patients without Detrusor Overactivity

August 31, 2011

GLASGOW—Intravesical botulinum toxin may be an effective treatment for overactive bladder (OAB) without detrusor overactivity (DOA) on urodynamic assessment, researchers reported at the International Continence Society annual meeting.
 

Approval Sought for New Overactive Bladder Drug

August 29, 2011

If cleared by the FDA, mirabegron would be the first oral treatment with a new mechanism of action for OAB in almost 30 years.
 

Antibiotics May Improve Treatment of Overactive Bladder

August 29, 2011

GLASGOW—Antibiotics may be a useful adjunctive treatment for overactive bladder (OAB), according to British researchers.
 

Trigonal Injections of Botulinum Toxin Improve OAB Outcomes

May 18, 2011

WASHINGTON, D.C.—Trigonal intradetrusor injections of botulinum toxin-A (BTX-A) results in greater reduction in overactive bladder (OAB) symptoms compared with trigone-sparing BTX-A injections, Irish investigators reported at the American Urological Association 2011 annual meeting.
 

Overactive Bladder Often Associated with Pelvic Organ Prolapse

May 18, 2011

WASHINGTON, D.C.—Posterior compartment pelvic organ prolapse (POP) in women is often associated with overactive bladder (OAB), and POP surgery may help to decrease OAB symptoms as well as detrusor overactive (DO), according to study findings presented at the American Urological Association 2011 annual meeting.
 

Surrogate Markers May Identify Age-Associated Biochemical Changes in OAB patients

May 18, 2011

WASHINGTON, D.C.—Urinary nerve growth factor (NGF) and MCP-1 may be surrogate markers for monitoring age-associated biochemical changes in patients with overactive bladder (OAB), according to data presented at the American Urological Association 2011 annual meeting.
 

'OAB-Dry' May Need to be Reassessed

May 17, 2011

WASHINGTON, D.C.—Questionnaires used to diagnose patients with overactive bladder (OAB) may identify anyone with polyuria, bladder hypersensitivity, and even OAB-wet with rare leakage episodes as OAB-dry, investigators reported at the American Urological Association 2011 annual meeting.
 

Overactive Bladder Found in One Fifth of Type 2 Diabetics

May 17, 2011

WASHINGTON, D.C—Japanese researchers found that more than one fifth of patients with type 2 diabetes receiving care at a dedicated diabetes center have overactive bladder (OAB).
 

Nocturia Is the Most Bothersome OAB Symptom in POTS Patients

May 17, 2011

WASHINGTON, D.C.—Nocturia is the most common overactive bladder (OAB) symptom affecting health-related quality of life (HRQL) in patients with postural tachycardia syndrome (POTS), investigators reported at the American Urological Association 2011 annual meeting.
 

Parkinson's Severity Associated with OAB Symptoms

May 17, 2011

WASHINGTON, D.C.—Overactive bladder (OAB) symptoms are common in patients with Parkinson's disease regardless of age and gender, and the severity of Parkinson's symptoms correlates with OAB symptoms, according to a study presented at the American Urological Association 2011 annual meeting.
 

OAB Symptoms Linked to Elevated Serum Leptin

May 16, 2011

WASHINGTON, D.C.—Elevation of serum leptin and a decrease in monocyte chemotactic protein-1 (MCP-1) levels are associated with overactive bladder (OAB) symptoms, according to new data presented at the American Urological Association 2011 annual meeting.
 

Sacral Neuromodulation Found Effective and Well-Tolerated

May 16, 2011

WASHINGTON, D.C.—Sacral neuromodulation with InterStim Therapy is safe and well tolerated as a treatment for patients with overactive bladder and those with urinary retention, French investigators reported at the American Urological Association 2011 annual meeting.
 

Adverse Events Common After Botulinum Toxin Injections

May 16, 2011

WASHINGTON, D.C.—Adverse events (AEs) after intravesical botulinum toxin type A for idiopathic detrusor overactivity (IDO) are encountered frequently, according to a new study presented at the American Urological Association 2011 annual meeting.
 

Botulinum Toxin Effective Long Term for Severe OAB

May 16, 2011

WASHINGTON, D.C.—Detrusor botulinum toxin type A injections are a safe and effective treatment long-term for patients with severe overactive bladder (OAB), Swiss researchers reported at the American Urological Association 2011 annual meeting.
 

OAB Affects Work Productivity

May 15, 2011

WASHINGTON, D.C.—Men and women who suffer from overactive bladder (OAB) report significantly greater levels of work limitations compared with those without urinary symptoms, according to a new study presented at the American Urological Association 2011 annual meeting.
 

Remission of Urologic Symptoms Not Uncommon

May 15, 2011

WASHINGTON, D.C.—The natural history of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) may involve as much remission as progression, according to a new longitudinal study presented at the American Urological Association 2011 annual meeting.
 

Overactive Bladder Highly Prevalent, Study Finds

May 14, 2011

WASHINGTON, D.C.—Overactive bladder (OAB) is highly prevalent in both women and men and the prevalence varies by race and ethnicity, according to study findings presented at the American Urological Association 2011 annual meeting.
 

BoNT-A Efficacy for Idiopathic Detrusor Overactivity Confirmed

March 21, 2011

VIENNA—Findings from a large randomized trial confirm the effectiveness of botulinum toxin type A (BoNT-A) for refractory idiopathic detrusor overactivity (IDO) in women.
 

Healthy Habits May Improve Urinary, Sexual Function

November 02, 2010

SAN FRANCISCO—Healthy lifestyle choices, such as not smoking and exercising regularly, may significantly impact urinary and sexual function, two studies suggest.
 

Fesoterodine for OAB Shows Efficacy at One Week

October 18, 2010

In a recent study, fesoterodine showed rapid onset of efficacy at one week in patients with overactive bladder (OAB) who were previously treated with tolterodine and dissatisfied with that drug.
 

Potential Gene Biomarkers for OAB Identified

September 01, 2010

TORONTO—An analysis of gene-expression patterns in women with overactive bladder (OAB) may point the way to possible new biomarkers for the condition.
 

Overactive Bladder Linked to Inflammation

May 29, 2010

SAN FRANCISCO—Increasing levels of C-reactive protein (CRP) are associated with increasing odds of overactive bladder (OAB), according to a population-based study of men and women.
 

PTNS Safe and Effective for Overactive Bladder

April 01, 2010

Percutaneous tibial nerve stimulation (PTNS) is safe and effective for treating overactive bladder (OAB) symptoms, a recent study shows.
 

Study: Most OAB Cases Go Untreated

February 05, 2010

The associated cost is a potential reason for undertreatment.
 

Study: Most Overactive Bladder Cases Go Untreated

January 11, 2010

Only 24.4% of patients aged 45 years and older take drugs for the condition, according to researchers.
 

PTNS Provides Sustained Overactive Bladder Relief

November 19, 2009

Study findings at 12 months showed prolonged significant improvements in objective urinary parameters.
 

OAB Meds Not Equal When It Comes To Adverse Effects

October 22, 2009

Solifenacin-treated patients experienced less dry mouth than those taking oxybutynin immediate release.
 

Nerve Stimulation An Overactive Bladder Option

September 17, 2009

Percutaneous tibial nerve stimulation may be considered an alternative treatment for overactive bladder (OAB), researchers reported in the Journal of Urology (2009;182:1055-1061).
 

Patent Issued for OAB Neuromodulation System

August 19, 2009

Uroplasty, Inc., a medical device company with headquarters in Minnetonka, Minn., has received a patent for its Urgent PC Neuromodulation System and stimulation methods for treating overactive bladder (OAB).
 

Novel Botox Therapy May Work for Idiopathic Refractory OAB

August 10, 2009

Researchers have reported encouraging results from a small study examining intravesical instillation of a botulinum toxin/dimethyl sulfoxide (DMSO) solution as a treatment for refractory idiopathic overactive bladder (OAB).
 

First and Only Topical Gel for Overactive Bladder Cleared

July 23, 2009

Watson Pharmaceuticals, Corona, Calif., has received approval for Gelnique (oxybutynin chloride) Gel 10%, the first and only topical gel for the treatment of overactive bladder (OAB).
 

Sacral Neuromodulation Can Ease Refractory Overactive Bladder in the Elderly

July 20, 2009

The procedure is ideal in this population because it is minimally invasive and highly efficacious
 

Diagnosing, Treating Refractory OAB

, April 02, 2009

Idiopathic overactive bladder (OAB) is a common condition in the United States, with a prevalence of 16% for men and 16.9% for women (World J Urol. 2003;20:327-336). OAB is costly, with related expenditures for 2000 estimated
 

Overactive Bladder Findings in Diabetic Women

April 02, 2009

Increased bladder sensation and detrusor overactivity are the most frequent urodynamic findings of overactive bladder (OAB) in women with diabetes, researchers in Taiwan reported in Neurourology and Urodynamics (2009; published online ahead of print).
 

Topical Gel for Overactive Bladder Approved

March 06, 2009

Gelnique (oxybutynin chloride) Gel 10%, the first and only topical gel for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, has received FDA approval.
 

New Daily Tablet to Treat OAB Approved

December 22, 2008

Toviaz (fesoterodine fumarate), manufactured by Schwarz Pharma of Zwickau, Germany, and distributed by Pfizer, has been approved to help patients suffering from overactive bladder (OAB).
 

LUTS Rates Expected to Soar Worldwide

September 01, 2008

PARIS—Investigators are predicting a significant increase in the number of individuals with lower urinary tract symptoms (LUTS) over the coming decade.
 

OAB Drug Works Despite Symptom Severity

September 01, 2008

PARIS—The severity of a patient's overactive bladder (OAB) symptoms prior to treatment with fixed-dose darifenacin (Enablex) has no effect on treatment response, researchers announced here at the Fourth International Consultation on Incontinence.
 

Experimental Agent Ameliorates OAB

July 21, 2008

MILAN—New data demonstrate that the investigational agent fesoterodine, at both the 4 or 8 mg per day dose, is associated with significant improvements in overactive bladder (OAB) symptoms.
 

Success with Replacement Bladders

June 30, 2008

ORLANDO—Researchers have succeeded in regenerating an entire urinary bladder in large mammals, according to new study findings presented here at the American Urological Association annual meeting.
 

Botulinum Toxin Treatment Failure Linked to Antibodies

May 01, 2008

Antibody responses could explain why some patients fail botulinum toxin type A (BoNT/A) treatment of hyperactive detrusor or sphincter dysfunction, according to German investigators.
 

Once-Daily Formulation for OAB Treatment Approved

September 01, 2007

Sanctura XR (trospium chloride extended-release capsules), made by Indevus Pharmaceuticals, Inc., of Lexington, Mass., has been approved for the once-daily treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
 

Key OAB Symptoms Not Related to Detrusor Overactivity

August 27, 2007

The cardinal symptoms of overactive bladder (OAB)—urinary urgency, frequency, and urge urinary incontinence—are not significantly associated with detrusor overactivity after adjustment for other risk factors, a study found.
 

Nearly 10% Have OAB

August 01, 2007

QUEBEC CITY—Nearly one in 10 Canadian adults suffer from overactive bladder (OAB), according to a population-based survey.
 

OAB in Men: A Diagnostic Challenge

July 01, 2007

Overactive bladder (OAB) is usually associated with women, but it afflicts nearly one out of every eight American men. Its symptoms can also be confused with those of BPH, resulting in unneeded surgery.
 

Overactive Bladder Boosts Risk of ED

January 01, 2007

Overactive bladder (OAB) symptoms in middle-aged or older men are associated with an increased risk of erectile dysfunction (ED).
 

Duloxetine May Relieve OAB Symptoms

January 01, 2007

Duloxetine, a serotonin-noradrenalin reuptake inhibitor, may be an effective treatment for women with symptoms of overactive bladder (OAB). Duloxetine is marketed as Cymbalta for treating depression and diabetic peripheral neuropathy.
 
Popular Topics
Acute Kidney Injury AKI Androgen Deprivation Anemia Benign Prostatic Hyperplasia Bladder Cancer BPH Cardiovascular Disease Chronic Kidney Disease Circumcision CKD CVD Dialysis End-stage Renal Disease Hemodialysis Kidney Cancer Overactive Bladder Prostate Cancer PSA Renal Cell Carcinoma Reproductive Medicine Secondary Hyperparathyroidism Transplantation Urinary Incontinence Urology

 

© 2012 Haymarket Media, Inc.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions